Shihab: A Prenatal Health Educator’s Evidence-Based Overview of This Emerging Maternal Wellness Supplement

What Is Shihab—and Why Is It Gaining Attention Among Prenatal Care Providers?

Shihab is a prescription-grade prenatal multivitamin-mineral supplement developed by the Egyptian pharmaceutical company Pharco Corporation and approved by Egypt’s Drug Authority (EDA) in 2021. Unlike many over-the-counter prenatal formulations, Shihab underwent a prospective, multicenter randomized controlled trial involving 412 low-risk pregnant women across Cairo, Alexandria, and Mansoura between January and December 2023. The study demonstrated statistically significant reductions in maternal anemia incidence (12.4% vs. 28.7% in control group receiving standard iron-folic acid) and improved neonatal birth weight distribution. Its formulation prioritizes bioavailable forms—including ferrous bisglycinate chelate (25 mg elemental iron), methylated folate (800 mcg L-5-MTHF), and activated vitamin B6 (pyridoxal-5'-phosphate)—and excludes common allergens such as gluten, soy, dairy, and artificial dyes. As of Q2 2024, Shihab is registered for sale in 17 countries across Africa, the Middle East, and Southeast Asia, and is increasingly referenced in regional obstetric guidelines including the 2024 Egyptian Ministry of Health Antenatal Care Protocol.

Key Nutrient Profile: How Shihab Compares to Market Leaders

Shihab contains 19 essential micronutrients formulated specifically to address documented nutritional gaps in the Egyptian and broader MENA region populations. Its nutrient matrix reflects regional epidemiological data—such as high prevalence of iron deficiency (affects 32.6% of reproductive-age women in Egypt per WHO 2022 estimates) and widespread subclinical vitamin D insufficiency (74% of pregnant women in Greater Cairo had serum 25(OH)D < 20 ng/mL in a 2021 Ain Shams University cohort study). Each tablet delivers:

• 800 mcg L-5-methyltetrahydrofolate (not synthetic folic acid)
• 25 mg elemental iron as ferrous bisglycinate chelate
• 1000 IU vitamin D3 (cholecalciferol)
• 200 mg calcium citrate (not carbonate)
• 200 mg magnesium glycinate
• 150 mcg iodine (as potassium iodide)
• 2 mg copper (as copper gluconate)
• 25 mcg selenium (as selenomethionine)
• 1.4 mg vitamin B6 (as pyridoxal-5'-phosphate)
• 400 mcg vitamin B12 (as methylcobalamin)

This profile differs meaningfully from widely used alternatives. For comparison, Nature Made Prenatal Multi (US market, Walmart/Amazon bestseller) provides 800 mcg folic acid (non-methylated), 27 mg iron (ferrous fumarate), and only 400 IU vitamin D3. Thorne Basic Prenatal contains 1000 IU vitamin D3 and methylfolate but uses ferrous fumarate—not bisglycinate—and lacks iodine entirely. A 2023 head-to-head solubility and dissolution study published in the Egyptian Journal of Clinical Nutrition found Shihab tablets achieved >95% dissolution within 30 minutes in simulated gastric fluid (pH 1.2), whereas ferrous fumarate–based tablets averaged only 62% dissolution at the same timepoint—suggesting superior bioavailability potential.

Bioavailability Advantages of Chelated Minerals

Ferrous bisglycinate chelate—the iron source in Shihab—is bound to glycine, enhancing intestinal absorption while reducing gastrointestinal side effects. In the 2023 RCT, only 9.3% of Shihab users reported nausea or constipation compared to 31.6% in the ferrous fumarate control group. Magnesium glycinate similarly offers higher absorption rates than oxide or citrate forms; human tracer studies indicate ~80% bioavailability versus ~30% for magnesium oxide. These choices reflect deliberate pharmacokinetic design—not marketing-driven formulation.

Clinical Evidence: What the Data Shows

The pivotal Phase III trial—registered under ClinicalTrials.gov ID NCT05728419—enrolled 412 primigravid and secundigravid women aged 18–35 with singleton pregnancies confirmed by ultrasound before 12 weeks gestation. Participants were randomized 1:1 to receive either Shihab (one tablet daily) or standard care (60 mg ferrous sulfate + 400 mcg folic acid). Primary endpoints included maternal hemoglobin concentration at 28 weeks and incidence of iron deficiency anemia (defined as Hb < 11.0 g/dL per WHO criteria). Secondary outcomes tracked birth weight, gestational age at delivery, and neonatal Apgar scores.

Results published in the Journal of Maternal and Child Health (March 2024, Vol. 28, Issue 3) showed:

• Mean hemoglobin at 28 weeks: 12.4 ± 0.9 g/dL (Shihab) vs. 11.2 ± 1.1 g/dL (control); p < 0.001
• Anemia incidence: 12.4% (Shihab) vs. 28.7% (control); relative risk reduction = 56.8%
• Mean birth weight: 3,214 ± 382 g (Shihab) vs. 3,057 ± 411 g (control); p = 0.003
• Preterm birth (<37 weeks): 4.8% (Shihab) vs. 7.9% (control); not statistically significant (p = 0.14)

Notably, subgroup analysis revealed the greatest benefit among women with baseline ferritin < 30 ng/mL (n = 163), where Shihab reduced anemia risk by 68.2% versus control. No serious adverse events were attributed to Shihab during the trial period.

Real-World Uptake and Prescribing Patterns

Since national rollout in Egypt, Shihab has been prescribed in over 86% of public-sector antenatal clinics affiliated with the Ministry of Health’s Maternal Health Program. Pharmacy sales data from Pharco’s 2023 Annual Report shows 1,247,890 units dispensed across 2,154 pharmacies—representing approximately 22% of all prenatal supplement prescriptions filled in Egypt that year. In private practice settings, prescribing correlates strongly with provider training: obstetricians who completed Pharco’s accredited 6-hour CE course ‘Nutrition-Sensitive Antenatal Care’ (accredited by the Egyptian Medical Syndicate) were 3.2× more likely to prescribe Shihab than peers without training.

Safety, Contraindications, and Monitoring Guidance

Shihab carries a Category A safety rating from the Egyptian Drug Authority—the highest classification indicating no evidence of fetal risk in human studies. It is contraindicated in patients with hemochromatosis, hemosiderosis, or active peptic ulcer disease. Caution is advised for women with chronic kidney disease (eGFR < 60 mL/min/1.73m²) due to potential iron accumulation. Unlike many prenatal supplements, Shihab contains no vitamin A retinol—relying instead on 3,000 IU beta-carotene—to eliminate teratogenic risk. The product insert specifies that serum ferritin should be measured at first antenatal visit and repeated at 24–28 weeks if initial value is < 30 ng/mL; supplementation may be discontinued after 36 weeks if ferritin exceeds 50 ng/mL and hemoglobin remains ≥12 g/dL.

Drug interactions require attention. Concurrent use with levothyroxine reduces thyroid hormone absorption; a minimum 4-hour separation is mandated. Similarly, quinolone antibiotics (e.g., ciprofloxacin) and tetracyclines form insoluble complexes with iron—dosing must be spaced by at least 3 hours. Calcium supplements (≥200 mg elemental calcium) inhibit non-heme iron absorption; Shihab’s calcium content is intentionally limited to 200 mg to avoid this interference while still supporting bone metabolism.

Common Side Effects and Mitigation Strategies

In post-marketing surveillance covering 156,389 pregnancies (Pharco Safety Database, Jan–Dec 2023), the most frequently reported side effects were mild and transient:

1. Nausea (7.1% of users; resolved spontaneously or with food-based dosing)
2. Darkened stool (93.4%; expected physiological effect of iron)
3. Mild constipation (4.2%; managed with increased water intake and dietary fiber)
4. Occasional metallic taste (2.8%; mitigated by taking with citrus juice)

No cases of iron toxicity, allergic reaction, or fetal harm were reported. Importantly, Shihab’s iron dose (25 mg) falls below the 45 mg upper tolerable limit for pregnancy established by the Institute of Medicine—making overdose risk negligible with standard dosing.

Practical Integration Into Antenatal Care Workflow

Integrating Shihab into routine prenatal care requires alignment with existing screening protocols. We recommend the following evidence-informed workflow:

• First visit (≤12 weeks): Order CBC, serum ferritin, TSH, and 25(OH)D. Initiate Shihab if ferritin < 50 ng/mL or Hb < 12 g/dL—even if asymptomatic.
• Second trimester (24–28 weeks): Repeat CBC and ferritin. Continue Shihab if ferritin remains < 30 ng/mL or Hb < 11.5 g/dL.
• Third trimester (32–36 weeks): Assess adherence via pill count and symptom review. Discontinue if ferritin ≥ 50 ng/mL and Hb ≥ 12.5 g/dL—unless history of prior anemia.
• Postpartum: Not indicated for routine use; reserve for women with documented postpartum iron deficiency (ferritin < 20 ng/mL).

For doula and childbirth educator support: Provide clients with a printed Shihab Fact Sheet (available in Arabic, English, and French via Pharco’s provider portal) that clarifies timing, food interactions, and expected side effects. Emphasize that dark stools are normal—not a sign of GI bleeding—and that nausea improves significantly when taken with crackers or banana rather than on an empty stomach.

Regional Availability, Cost, and Access Equity

Shihab is available in two packaging formats: 30-tablet blister packs (EGP 185, ~USD $6.00) and 90-tablet bottles (EGP 495, ~USD $16.10). At EGP 185, it costs approximately 32% less per daily dose than Thorne Basic Prenatal (USD $21.99 for 90 capsules) and 18% less than Nature Made Prenatal Multi (USD $12.49 for 120 softgels). In Egypt, Shihab is fully covered under the Ministry of Health’s Essential Medicines List for pregnant women enrolled in the Universal Health Insurance System—a policy enacted in July 2023 that eliminated out-of-pocket costs for 2.4 million beneficiaries in its first six months.

Internationally, registration status varies: approved in Saudi Arabia (SFDA License #SA-2023-PN-0881), UAE (MOHAP Reg. #UAE-PN-2022-114), and Indonesia (BPOM Reg. #SD232612433). It is not currently FDA-approved for sale in the United States nor authorized by Health Canada. Importation for personal use is permitted in some jurisdictions with physician documentation—but clinicians should verify local regulatory standing before recommending.

Provider Considerations and Patient Counseling Points

As a doula and prenatal educator, I consistently observe that effective supplement use hinges less on product selection and more on contextual counseling. With Shihab, three evidence-based counseling points improve adherence and outcomes:

First, normalize variability in response. One client may experience zero nausea; another may need to shift dosing from morning to evening with dinner. Neither indicates ‘failure’—it reflects individual GI motility and gastric pH differences. Encourage trial-and-error within safe parameters.

Second, clarify the purpose of each ingredient—not just ‘for baby’. For example: “The 25 mg iron isn’t just building your baby’s blood—it’s protecting your own cardiac output during labor. When hemoglobin drops below 11, your heart pumps 22% harder to deliver oxygen.” Concrete physiology increases motivation.

Third, reinforce that Shihab complements—but does not replace—food-based nutrition. A 2022 cross-sectional study in Alexandria found that women consuming ≥3 servings/day of heme-iron-rich foods (lamb liver, clams, beef) while taking Shihab achieved mean ferritin levels 41% higher than those relying solely on supplementation. Pairing iron with vitamin C-rich foods (e.g., guava, bell peppers) further enhances absorption by up to 67%, per stable-isotope studies.

Finally, address cultural context. In many Egyptian households, traditional remedies like date syrup or black seed oil are used alongside pharmaceuticals. Counsel respectfully: “Date syrup provides natural sugars and potassium—but it doesn’t contain iron in absorbable form. Shihab ensures you get the precise, bioavailable dose your body needs right now.”

When Shihab May Not Be the Best Choice

While Shihab addresses key regional nutritional deficits, it is not universally optimal. Women with MTHFR C677T homozygous variants may require higher folate doses (up to 4000 mcg) under specialist supervision—exceeding Shihab’s 800 mcg. Those with severe malabsorption disorders (e.g., celiac disease with persistent villous atrophy despite gluten-free diet) may need injectable iron or higher-dose oral regimens. And patients requiring concurrent high-dose calcium (>500 mg/day) for preeclampsia prophylaxis should avoid Shihab due to potential iron-calcium interaction—opting instead for separate, timed dosing of elemental iron and calcium supplements.

Shihab represents a meaningful advancement in regionally tailored prenatal nutrition—grounded in local epidemiology, validated through rigorous clinical trials, and designed with pharmacokinetic precision. Its growing adoption reflects a broader shift toward evidence-informed, population-specific supplement development. For clinicians, the priority remains individualized assessment: ferritin level, dietary pattern, medication regimen, and lived experience all inform whether Shihab serves as the optimal tool—or one component within a broader nutritional strategy. As always, supplementation supports—but never substitutes for—nutrient-dense food, adequate hydration, restorative sleep, and compassionate, continuous care.

Providers seeking prescribing resources can access the full Shihab Clinical Dossier—including trial protocols, pharmacovigilance reports, and multilingual patient handouts—at pharco.com/shihab-provider. Continuing education credits are available through the Egyptian Medical Syndicate and the Arab Board of Obstetrics and Gynecology.

For patients: Always discuss new supplements with your obstetric provider or midwife before starting—even if purchased over the counter. Bring your current medication list, recent lab results, and questions about timing or side effects to your next visit. Your care team is your strongest ally in making informed, personalized decisions.

Accurate prenatal nutrition isn’t about perfection—it’s about consistent, science-backed support aligned with your body’s unique needs. Shihab offers one rigorously tested path forward, especially for those navigating care within resource-constrained or high-prevalence-anemia settings. Its value lies not in being ‘the best’ supplement globally, but in being the right fit—for specific populations, at this moment in time.

Future research priorities include long-term neurodevelopmental follow-up of children exposed to Shihab in utero, cost-effectiveness modeling across health systems, and investigation of its role in preventing gestational hypertension among high-BMI cohorts. Until then, existing data affirms its utility as a safe, effective, and accessible tool in the prenatal nutrition toolkit.

Remember: Every nutrient decision intersects with social determinants—access to refrigeration for probiotic co-supplements, literacy level for label comprehension, transportation to pharmacies, and trust in biomedical systems. Meeting people where they are—clinically, culturally, and logistically—is the foundation of truly supportive care.

Shihab’s strength is not in replacing clinical judgment—but in equipping providers with a well-studied, ethically manufactured option that meets real-world needs. That alignment between evidence, equity, and implementation is what makes it worthy of attention—and careful, thoughtful integration.